收费全文 | 10131篇 |
免费 | 761篇 |
国内免费 | 34篇 |
耳鼻咽喉 | 64篇 |
儿科学 | 276篇 |
妇产科学 | 200篇 |
基础医学 | 1549篇 |
口腔科学 | 155篇 |
临床医学 | 1316篇 |
内科学 | 1889篇 |
皮肤病学 | 178篇 |
神经病学 | 937篇 |
特种医学 | 274篇 |
外科学 | 946篇 |
综合类 | 205篇 |
一般理论 | 16篇 |
预防医学 | 1161篇 |
眼科学 | 200篇 |
药学 | 772篇 |
中国医学 | 11篇 |
肿瘤学 | 777篇 |
2023年 | 67篇 |
2022年 | 113篇 |
2021年 | 180篇 |
2020年 | 168篇 |
2019年 | 209篇 |
2018年 | 228篇 |
2017年 | 199篇 |
2016年 | 242篇 |
2015年 | 285篇 |
2014年 | 330篇 |
2013年 | 482篇 |
2012年 | 672篇 |
2011年 | 826篇 |
2010年 | 417篇 |
2009年 | 406篇 |
2008年 | 605篇 |
2007年 | 632篇 |
2006年 | 607篇 |
2005年 | 624篇 |
2004年 | 554篇 |
2003年 | 573篇 |
2002年 | 533篇 |
2001年 | 143篇 |
2000年 | 112篇 |
1999年 | 148篇 |
1998年 | 132篇 |
1997年 | 100篇 |
1996年 | 87篇 |
1995年 | 73篇 |
1994年 | 73篇 |
1993年 | 68篇 |
1992年 | 73篇 |
1991年 | 72篇 |
1990年 | 78篇 |
1989年 | 60篇 |
1988年 | 55篇 |
1987年 | 46篇 |
1986年 | 59篇 |
1985年 | 54篇 |
1984年 | 56篇 |
1983年 | 37篇 |
1982年 | 46篇 |
1981年 | 31篇 |
1980年 | 29篇 |
1979年 | 36篇 |
1978年 | 25篇 |
1977年 | 32篇 |
1976年 | 30篇 |
1974年 | 22篇 |
1972年 | 24篇 |
The metabolism of the pyrethroids deltamethrin (DLM), cis-permethrin (CPM) and trans-permethrin (TPM) was studied in human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes.
DLM, CPM and TPM were metabolised by human CYP2B6 and CYP2C19, with the highest apparent intrinsic clearance (CLint) values for pyrethroid metabolism being observed with CYP2C19. Other CYP enzymes contributing to the metabolism of one or more of the three pyrethroids were CYP1A2, CYP2C8, CYP2C9*1, CYP2D6*1, CYP3A4 and CYP3A5. None of the pyrethroids were metabolised by CYP2A6, CYP2E1, CYP3A7 or CYP4A11.
DLM, CPM and TPM were metabolised by both human CES1 and CES2 enzymes.
Apparent CLint values for pyrethroid metabolism by CYP and CES enzymes were scaled to per gram of adult human liver using abundance values for microsomal CYP enzymes and for CES enzymes in liver microsomes and cytosol. TPM had the highest and CPM the lowest apparent CLint values for total metabolism (CYP and CES enzymes) per gram of adult human liver.
Due to their higher abundance, all three pyrethroids were extensively metabolised by CES enzymes in adult human liver, with CYP enzymes only accounting for 2%, 10% and 1% of total metabolism for DLM, CPM and TPM, respectively.
Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献